Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety and Performance of INT001 in the Percutaneous Ablation of Liver Tumors: A Prospective, Single-arm, Single-center Clinical Study

NCT06689670 is registered in ClinicalTrials.gov with inTumo Therapeutics, Inc. as lead sponsor.

NCT NCT06689670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06689670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety and Performance of INT001 in the Percutaneous Ablation of Liver Tumors: A Prospective, Single-arm, Single-center Clinical Study
Lead sponsor
inTumo Therapeutics, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
October 28, 2024
Completion date
December 31, 2027
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma, liver tumors, metastatic liver tumor